Literature DB >> 3167770

A unique pattern of proto-oncogene abnormalities in ovarian adenocarcinomas.

D J Zhou1, N Gonzalez-Cadavid, H Ahuja, H Battifora, G E Moore, M J Cline.   

Abstract

Twelve cases of ovarian adenocarcinoma were studied for alterations in proto-oncogenes, and a unique pattern of altered ras proto-oncogenes was observed. Amplification of ras-Ki was found in three of seven ovarian tumors and amplification of ras-Ha in one of 12. In contrast, ras-Ha amplification was not found in any of the 334 other tumors and ras-Ki amplification was only seen in breast cancer at a frequency of 3%. Other proto-oncogenes altered in ovarian adenocarcinomas included c-myc and c-erbb-2. Proto-oncogene abnormalities were more frequent in aggressive tumors of high histologic grade.

Entities:  

Mesh：

Year:  1988        PMID： 3167770     DOI： 10.1002/1097-0142(19881015)62:8<1573::aid-cncr2820620819>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  10 in total

1.  C-myc proto-oncogene amplification detected by polymerase chain reaction in archival human ovarian carcinomas.

Authors:  G Schreiber; L Dubeau
Journal:  Am J Pathol       Date:  1990-09       Impact factor: 4.307

2.  DNA ploidy and MYC DNA amplification in ovarian carcinomas. Correlation with p53 and bcl-2 expression, proliferative activity and prognosis.

Authors:  J Diebold; B Suchy; G B Baretton; S Blasenbreu; W Meier; M Schmidt; H Rabes; U Löhrs
Journal:  Virchows Arch       Date:  1996-11       Impact factor: 4.064

3.  Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.

Authors:  Kathleen M Darcy; William E Brady; Jan K Blancato; Robert B Dickson; William J Hoskins; William P McGuire; Michael J Birrer
Journal:  Gynecol Oncol       Date:  2009-06-12       Impact factor: 5.482

4.  Relationship of myc protein expression to the phenotype and to the growth potential of HOC-7 ovarian cancer cells.

Authors:  C Somay; T W Grunt; C Mannhalter; C Dittrich
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

Review 5.  c-MYC and Epithelial Ovarian Cancer.

Authors:  Jeyshka M Reyes-González; Pablo E Vivas-Mejía
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

6.  Chromosomal localisation of two putative 11p oncosuppressor genes involved in human ovarian tumours.

Authors:  A Viel; F Giannini; L Tumiotto; F Sopracordevole; M C Visentin; M Boiocchi
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

7.  Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.

Authors:  K Niwa; M Itoh; T Murase; S Morishita; N Itoh; H Mori; T Tamaya
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

8.  Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas.

Authors:  J M Arnold; S C Mok; D Purdie; G Chenevix-Trench
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

9.  Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.

Authors:  M Fujita; T Enomoto; M Inoue; O Tanizawa; M Ozaki; J M Rice; T Nomura
Journal:  Jpn J Cancer Res       Date:  1994-12

10.  High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy.

Authors:  T Kihana; H Tsuda; S Teshima; S Okada; S Matsuura; S Hirohashi
Journal:  Jpn J Cancer Res       Date:  1992-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.